Among these monocyte populations, the counts of monocytes that expressed higher levels of CD62L (Mo F+L+; monocytes expressing SiglecF and CD62L) had large fold changes and small p-values (larger -log2(p)) between the groups, and notably had minimal count overlap between the tumor-bearing groups and no-tumor controls, thus representing a suitable marker to distinguish cancer presence. The gene discussed is SELL; the disease is cancer.